Journal of Molecular Science

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

Journal of Molecular Science
www.jmolecularsci.com ISSN:1000-9035

Nanomicelle-Loaded In Situ Gels for Uveitis Therapy: A Comprehensive Review

Mr. Akashdeep Udmale, *[1] Ms. Suhani Ashok Bonawate[2], Mr. Aryan UlhasAngre[3], Mr. Rafid Ibrahim Patel[4] , Dr. Ganesh Deshmukh [5]

[1-5]Department of Pharmaceutics, D.Y. Patil Deemed to be University School of Pharmacy, Nerul Navi Mumbai-400 706

Article Information
Received: 12-09-2025
Revised: 06-10-2025
Accepted: 26-10-2025
Published: 14-11-2025

Keywords
Uveitis, Nanomicelles, In Situ Gel, Ocular Drug Delivery, Corticosteroids, Drug Targeting, Nanotechnology, Sustained Release, Bioavailability, Ocular Barriers.

ABSTRACT

Objective: To provide a comprehensive review of the synergistic potential of nanomicelle-loaded in situ gelling systems as an advanced ocular drug delivery platform for the treatment of uveitis.

Main Body: Uveitis, a significant cause of visual impairment, presents therapeutic challenges due to formidable ocular barriers and the inherent limitations of conventional treatments. This review critically analyzes current uveitis therapies, highlighting persistent issues of low bioavailability, the need for frequent dosing, and significant local and systemic side effects. It then delves into the individual technologies of nanomicelles—which excel at solubilizing hydrophobic drugs and enhancing corneal penetration—and in situ gels, which prolong precorneal residence time by transitioning from a solution to a gel upon instillation. The core of this review focuses on the compelling rationale and intricate mechanism of combining these two platforms into a single, advanced delivery system. We synthesize and analyze key preclinical and clinical evidence for the delivery of mainstay anti-inflammatory agents, including corticosteroids (e.g., dexamethasone, difluprednate, prednisolone) and immunosuppressants (e.g., cyclosporine A, voclosporin). The analysis concentrates on formulation strategies, critical characterization parameters, and therapeutic efficacy demonstrated in relevant endotoxin-induced uveitis models and other preclinical studies.

Conclusion: The integration of drug-loaded nanomicelles within stimuli-responsive in situ gels represents a highly promising, non-invasive strategy to substantially improve therapeutic outcomes in uveitis. This synergistic approach enhances drug bioavailability, provides sustained and controlled release kinetics, and improves patient compliance by reducing dosing frequency. We also discuss the existing challenges that impede clinical translation, including manufacturing scalability and complex regulatory pathways, and outline future directions for research and development to bring this next-generation therapy from the bench to the bedside.

1. INTRODUCTION:

The Unmet Needs in Uveitis Management

Ocular inflammatory diseases represent a major global health burden, with uveitis standing out as a leading cause of severe visual impairment and blindness, particularly among the working-age population [1, 2]. The term 'uveitis' encompasses a heterogeneous group of disorders characterized by inflammation of the uveal tract—comprising the iris, ciliary body, and choroid—but often extends to involve adjacent structures such as the retina,

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

vitreous, and optic nerve [3]. The management of uveitis is a complex clinical challenge, driven not by a scarcity of potent therapeutic agents, but by the profound difficulty of delivering these drugs to the target intraocular tissues at therapeutic concentrations without inducing significant toxicity [4]. This delivery conundrum has spurred intensive research into advanced drug delivery systems, aiming to revolutionize the treatment paradigm for this sight-threatening condition.

1.1. Uveitis: A Sight-Threatening Inflammatory Disease

The pathophysiology of uveitis is complex and not fully elucidated, often involving a dysregulated immune response. In non-infectious uveitis, which accounts for a majority of cases in developed nations, the inflammation is believed to be autoimmune, potentially triggered by molecular mimicry where the immune system mistakenly targets ocular self-antigens [5]. This process is largely mediated by T-helper cells (Th1 and Th17), leading to a cascade of inflammatory cytokine release and subsequent tissue damage [6]. Infectious etiologies, including viral (e.g., HSV, CMV), bacterial (e.g., syphilis, tuberculosis), and parasitic agents, account for approximately 20% of cases and require specific antimicrobial therapy alongside anti-inflammatory treatment [3].

Uveitis is anatomically classified based on the primary site of inflammation, a system crucial for diagnosis and treatment planning [3]:

- **Anterior Uveitis:** The most common form, affecting the iris and ciliary body. It typically presents with pain, photophobia, and redness.
- **Intermediate Uveitis:** Characterized by inflammation primarily in the vitreous cavity and pars plana, often presenting with floaters and blurred vision.
- **Posterior Uveitis:** Inflammation of the retina and/or choroid, which poses a direct threat to vision.
- **Panuveitis:** Involves inflammation of all layers of the uvea.

Regardless of the location, uncontrolled or chronic inflammation can lead to devastating and often irreversible complications. These sequelae are the primary drivers of vision loss in uveitis patients. Among the most prevalent is Cystoid Macular Edema (CME), a condition where fluid accumulates in the macula, the central part of the retina responsible for sharp, detailed vision [7]. Other significant complications include the formation of cataracts due to chronic inflammation or steroid use, glaucoma (elevated intraocular pressure, IOP), posterior synechiae (adhesions between the iris and lens), and retinal detachment [8]. The high incidence of these complications underscores the critical need for early, aggressive, and sustained control of intraocular inflammation.
Optical Coherence Tomography (OCT) showing cystoid macular edema (CME), a common sight-threatening complication of uveitis, characterized by fluid-filled cysts in the macular region.

1.2. Critical Review of Current Therapeutic Landscape

The therapeutic armamentarium for non-infectious uveitis is extensive, following a stepwise approach aimed at rapidly quenching inflammation and preventing recurrence. However, each modality is encumbered by a distinct set of limitations, primarily related to drug delivery and side effects [9].

First-line Therapies: Corticosteroids:
Corticosteroids are the cornerstone of uveitis management due to their potent and rapid anti-inflammatory action [10]. They are administered via multiple routes, each with a unique risk-benefit profile:

- **Topical Corticosteroids:** Eye drops (e.g., prednisolone acetate 1%, difluprednate 0.05%) are the mainstay for anterior uveitis. However, their efficacy is severely limited by poor corneal penetration and rapid clearance from the ocular surface, often requiring intensive dosing regimens (e.g., hourly) that compromise patient adherence [11].
- **Periocular and Intravitreal Injections:** For intermediate, posterior, or severe anterior uveitis, local injections (e.g., triamcinolone acetonide) or intravitreal implants (e.g., dexamethasone, fluocinolone acetonide) can deliver high drug concentrations directly to the site of inflammation, bypassing anterior barriers [12, 13]. While effective, these invasive procedures carry risks of IOP elevation, cataract formation, endophthalmitis, and retinal detachment, and can cause significant patient anxiety [14].

- **Systemic Corticosteroids:** Oral or intravenous corticosteroids are reserved for bilateral, severe, or posterior segment disease. Long-term use is fraught with well-documented systemic side effects, including osteoporosis, diabetes, weight gain, hypertension, and increased susceptibility to infection, making them unsuitable for chronic management [15].

Steroid-Sparing Agents: Immunosuppressants & Biologics
For patients with chronic uveitis or those intolerant to corticosteroids, steroid-sparing agents are introduced to maintain long-term inflammatory

Journal of Molecular Science
Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

control [16].

- **Conventional Immunosuppressants:** Antimetabolites like methotrexate (MTX) and mycophenolate mofetil (MMF) are common first-line choices. The FAST trial demonstrated their comparable efficacy in controlling inflammation [17]. Calcineurin inhibitors such as cyclosporine and tacrolimus are also used, particularly for severe cases [18]. However, all these agents require systemic administration and are associated with potential organ toxicity (e.g., hepatotoxicity with MTX, nephrotoxicity with calcineurin inhibitors), necessitating regular monitoring.

- **Biologic Agents:** The advent of biologics, particularly TNF-α inhibitors, has revolutionized the treatment of refractory uveitis. Adalimumab is FDA-approved for non-infectious intermediate, posterior, and panuveitis based on the pivotal VISUAL I and II trials, which showed a significant reduction in the risk of treatment failure compared to placebo [19, 20]. Despite their efficacy, biologics are expensive, require subcutaneous or intravenous administration, and carry risks of serious infections and other immune-related adverse events.

Modality	Route of Administration	Primary Indications	Advantages	Significant Limitations/Side Effects
Topical Corticosteroids (e.g., prednisolone, difluprednate)	Topical (Eye Drops)	Anterior uveitis	Mainstay of treatment, rapid anti-inflammatory action.	Poor corneal penetration, rapid clearance, requires frequent (e.g., hourly) dosing, poor patient compliance.
Periocular/Intravitreal Corticosteroids (e.g., triamcinolone, dexamethasone implant)	Periocular/Intravitreal Injection or Implant	Intermediate, posterior, or severe anterior uveitis	Delivers high drug concentration directly to the target site, bypasses anterior barriers.	Invasive procedure; risks of IOP elevation, cataract, endophthalmitis, retinal detachment; patient anxiety.
Systemic Corticosteroids	Oral or Intravenous (IV)	Bilateral, severe, or posterior segment disease	Potent and effective for widespread or difficult-to-reach inflammation.	Unsuitable for chronic use due to severe systemic side effects (osteoporosis, diabetes, hypertension, weight gain).
Conventional Immunosuppressants (e.g., MTX, MMF, cyclosporine)	Systemic (Oral)	Chronic uveitis, steroid-intolerant patients	Effective as steroid-sparing agents for long-term control.	Systemic administration required; potential for significant organ toxicity (liver, kidney); requires regular monitoring.
Biologic Agents (e.g., Adalimumab)	Subcutaneous or Intravenous (IV)	Refractory non-infectious intermediate, posterior, and panuveitis	Highly effective for severe, treatment-resistant cases.	Very expensive; requires injection/infusion; risk of serious infections and other immune-related adverse events.

1.3. The Delivery Dilemma

A critical analysis of the current therapeutic landscape reveals a recurring theme: the primary obstacle to effective and safe uveitis management is not the absence of potent drugs, but the profound challenge of delivering them to the specific site of inflammation within the eye. Conventional delivery methods represent a trade-off between efficacy and safety. Topical routes are safe but often ineffective for deeper structures, while systemic and local invasive routes are more effective but carry a heavy burden of side effects and risks [4, 21]. This "delivery dilemma" creates a significant unmet clinical need for a non-invasive, targeted, and sustained drug delivery system that can enhance therapeutic efficacy while minimizing toxicity and improving patient compliance. It is this challenge that has catalyzed the exploration of nanotechnology-based platforms.

2. The Challenge of Ocular Drug Delivery: Overcoming the Eye's Fortifications

The human eye is a remarkably well-protected organ, equipped with a sophisticated series of anatomical and physiological barriers that shield it from external threats. While essential for preserving vision, these same fortifications pose a formidable challenge to pharmaceutical scientists, severely limiting the ability of therapeutic agents to reach their intended targets [22]. Understanding these barriers is fundamental to appreciating the limitations of conventional formulations and the rationale behind developing advanced delivery systems.

Journal of Molecular Science
Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

2.1. Anatomical and Physiological Barriers:
Ocular barriers can be broadly categorized into those affecting topical delivery to the anterior segment and those restricting access to the posterior segment from systemic circulation.

Anterior Segment Barriers:
When a drug is administered topically as an eye drop, it immediately encounters several dynamic and static barriers:

- **Tear Film Dynamics:** The precorneal tear film, with a resident volume of only 7-10 µL, is constantly being replenished and drained. An instilled eye drop (typically 30-50 µL) largely exceeds this capacity, leading to immediate spillage. The remaining drug is rapidly diluted and washed away into the nasolacrimal duct at a turnover rate of approximately 16% per minute, drastically reducing the drug's residence time on the ocular surface [23].

- **The Cornea:** The cornea is the primary pathway for drug entry into the anterior chamber, but it is a highly selective, multi-layered barrier. Its outer epithelium is lipophilic, hindering the passage of hydrophilic drugs. Conversely, the underlying stroma, which constitutes 90% of corneal thickness, is highly hydrated and hydrophilic, impeding the transport of lipophilic drugs. This "amphiphilic" barrier structure means that a drug must possess a delicate balance of lipophilicity and hydrophilicity to effectively permeate [24].

- **The Conjunctiva:** While offering a much larger surface area than the cornea, the conjunctiva is highly vascularized. Drugs absorbed across the conjunctiva are rapidly cleared into systemic circulation, reducing the amount available for intraocular penetration and potentially causing systemic side effects [22].

Posterior Segment Barriers
Delivering drugs to the back of the eye is even more challenging, whether attempted topically or systemically.

- **Blood-Ocular Barriers:** Analogous to the blood-brain barrier, the eye is protected by the blood-aqueous barrier (BAB) and the blood-retinal barrier (BRB). The BAB, formed by tight junctions in the ciliary body and iris vasculature, restricts drug passage from the blood into the anterior chamber. The BRB, composed of tight junctions in the retinal capillary endothelium (inner BRB) and the retinal pigment epithelium (RPE) (outer BRB), severely limits the entry of drugs from systemic circulation into the retina and vitreous [25]. These barriers are so effective that systemic therapies often require high doses to achieve therapeutic intraocular concentrations, leading to increased systemic toxicity.

- **Vitreous Humor:** For drugs that do enter the posterior segment (e.g., via intravitreal injection), the vitreous humor itself acts as a barrier. This gel-like matrix, composed mostly of water, collagen, and hyaluronic acid, can hinder the diffusion of large molecules to the retina [24].



Figure 1. A cross-section of the human eye illustrating the static (cornea, sclera, blood-retinal barrier) and dynamic (tear turnover, conjunctival clearance) barriers that impede drug delivery from both topical and systemic routes.

2.2. Consequences for Conventional Formulations
The cumulative effect of these barriers is a dramatic reduction in the bioavailability of drugs administered via conventional methods. For topical eye drops, it is estimated that less than 5% of the administered dose actually reaches the aqueous humor, with even less penetrating to posterior tissues [26]. This abysmal bioavailability has several critical consequences:

1. Frequent Administration: To maintain a therapeutic drug concentration, patients must apply eye drops multiple times per day. For severe inflammation, this can be as frequent as every hour, which is highly disruptive and difficult to maintain.

2. Poor Patient Compliance: High dosing frequency inevitably leads to poor patient adherence, a well-documented problem in ophthalmic care. Missed doses can lead to breakthrough inflammation and disease progression [27].

3. Increased Side Effects: The "wasted" 95% of the drug does not simply disappear. It is absorbed systemically via the nasolacrimal duct and conjunctival vessels, potentially causing unintended systemic side effects. Furthermore, the high peak concentrations immediately after instillation can contribute to local toxicity on the ocular surface.

The fundamental challenge in ocular pharmacotherapy is therefore to design a delivery system that can intelligently navigate or bypass

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

these barriers, prolonging drug residence time at the target site and enabling controlled release to maintain a steady therapeutic effect.

3. Advanced Drug Delivery Platforms: The Building Blocks

To address the profound challenges of ocular drug delivery, researchers have turned to nanotechnology and advanced polymer science. Two platforms have emerged as particularly promising for topical application: nanomicelles, which enhance drug solubility and permeation, and in situ gelling systems, which prolong drug residence time. Understanding their individual mechanisms is key to appreciating their synergistic potential.

3.1. Part I: Nanomicelles for Enhanced Solubility and Permeation

Fundamental Principles

Nanomicelles are nanosized colloidal dispersions, typically ranging from 10 to 100 nm in diameter, that spontaneously self-assemble in an aqueous medium from amphiphilic molecules (surfactants or block copolymers) when their concentration exceeds a threshold known as the Critical Micelle Concentration (CMC) [28]. These structures possess a unique core-shell architecture: a hydrophobic (lipophilic) inner core and a hydrophilic outer shell (corona) [29]. This amphiphilic nature makes them ideal carriers for drugs that are poorly soluble in water, a characteristic of many potent corticosteroids and immunosuppressants used in uveitis therapy [30].

Mechanism in Ocular Delivery

Nanomicelles enhance ocular drug delivery through a multi-pronged mechanism:

1. Solubilization: The hydrophobic core acts as a nano-reservoir, encapsulating water-insoluble drug molecules. This allows for the formulation of clear, aqueous eye drops with high drug loading, overcoming a major hurdle for drugs like dexamethasone, cyclosporine, and difluprednate, which are typically formulated as blurry emulsions or suspensions that can cause patient discomfort and dose variability [31, 32].

2. Enhanced Permeation: The small size of nanomicelles (often < 30 nm) facilitates their transport through the aqueous pores of the corneal and scleral tissues [33]. The hydrophilic PEGylated shell helps them navigate the protective mucus layer of the tear film. Furthermore, certain surfactants used to form nanomicelles, such as D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), can act as permeation enhancers and inhibitors of efflux pumps like P-glycoprotein (P-gp), which actively pump drugs out of cells, thereby increasing intracellular drug accumulation [34].

3. Stability and Protection: By sequestering the drug within their core, nanomicelles protect it from enzymatic degradation by enzymes present in the tear film, prolonging its active lifespan on the ocular surface [29]. Polymeric micelles, in particular, exhibit high thermodynamic and kinetic stability due to their very low CMC values, ensuring they do not prematurely dissociate upon dilution with tear fluid [35].

Formulation Materials

The choice of material is critical for safety and efficacy. For ocular applications, materials must be non-irritating and biocompatible. Several FDA-approved excipients are commonly used:

- **Polymeric Micelles:** Formed from amphiphilic block copolymers. The hydrophilic block is often polyethylene glycol (PEG) due to its excellent biocompatibility and "stealth" properties, while the hydrophobic block can be a biodegradable polyester like poly(ε-caprolactone) (PCL) or polylactic acid (PLA) [36]. Grafted copolymers like Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol) are also widely used to enhance solubility [37].
- **Surfactant Micelles:** Formed from non-ionic surfactants, which are generally safer for ocular use than their ionic counterparts. Commonly used examples include Vitamin E TPGS, polysorbates (e.g., Polysorbate 80), poloxamers (e.g., Pluronic® series), and polyoxyl hydrogenated castor oils (e.g., Kolliphor® RH 40) [38, 39].

3.2. Part II: In Situ Gelling Systems for Sustained Release

Fundamental Principles

In situ gelling systems are "smart" polymeric solutions that are administered as a low-viscosity liquid (eye drop) but undergo a rapid sol-to-gel phase transition upon instillation into the eye's cul-de-sac [40]. This transformation is triggered by the physiological conditions of the eye, such as temperature, pH, or ion concentration.

Stimuli-Responsive Mechanisms

The gelation mechanism depends on the type of polymer used:

1. Thermo-responsive Gels: These systems utilize polymers that exhibit a Lower Critical Solution Temperature (LCST). Below the LCST, the polymer chains are hydrated and soluble, forming a liquid. Above the LCST, they dehydrate and aggregate to form a gel. Poloxamers, particularly Poloxamer 407 (Pluronic® F-127), are the most studied thermo-responsive polymers. They are liquid at refrigerated or room temperature but gel at the physiological temperature of the eye (~34-35°C) [41].

Journal of Molecular Science
Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

2. pH-responsive Gels: These are based on polyelectrolytes containing acidic or basic functional groups. For example, polyacrylic acid (e.g., Carbopol®) is formulated at an acidic pH (~4.5-5.0) where its carboxylic groups are protonated, and the polymer chains are coiled. Upon contact with the neutral pH of tears (~7.4), the groups ionize, leading to electrostatic repulsion, chain uncoiling, and gel formation [42].

3. Ion-activated Gels: These polymers undergo gelation in the presence of cations found in tear fluid. Gellan gum (Gelrite®) is a prime example. It is an anionic polysaccharide that forms a cross-linked hydrogel network upon interaction with monovalent (Na+) and divalent (Ca2+) cations in tears [43].

Polymer Type	Example(s)	Trigger Mechanism	Key Properties & Mechanism of Action
Thermo-responsive	Poloxamers (e.g., Pluronic® F-127)	Temperature	Liquid at refrigerated/room temperature (~20-25°C), undergoes sol-to-gel transition at physiological eye temperature (~34-35°C).
pH-responsive	Polyacrylic acid (e.g., Carbopol®)	pH	Formulated at an acidic pH (~4.5-5.0) as a low-viscosity liquid. Gels upon contact with neutral tear fluid (pH ~7.4) due to ionization and chain uncoiling.
Ion-activated	Gellan gum (e.g., Gelrite®)	Ions	Anionic polysaccharide that forms a cross-linked hydrogel network in the presence of mono- and divalent cations (Na+, Ca2+) found in tear fluid.

Mechanism in Ocular Delivery

The in-situ formation of a gel depot on the ocular surface provides two major advantages:

1. Prolonged Precorneal Residence Time: The viscous gel adheres to the mucus layer of the conjunctiva and resists the rapid washout caused by blinking and tear drainage. This dramatically increases the contact time of the drug with the ocular surface from minutes to several hours [40].

2. Sustained Drug Release: The cross-linked polymer network of the gel acts as a matrix from which the drug is released in a slow, controlled manner via diffusion. This avoids the "peak and trough" concentration profile of conventional eye drops, maintaining a more stable therapeutic level of the drug over an extended period [44].

3. Improved Patient Compliance: By providing sustained release, in situ gels can significantly reduce the required dosing frequency, often from multiple times a day to just once or twice daily. This enhances patient convenience and adherence to the treatment regimen, which is critical for managing chronic conditions like uveitis [45].



Figure 2. Schematic illustration of the core technologies. (A) The structure of a drug-loaded nanomicelle, showing the hydrophobic drug encapsulated within the core and the hydrophilic shell providing aqueous stability. (B) The sol-to-gel transition of a stimuli-responsive in situ gelling system upon instillation into the ocular environment.

4. The Synergistic Approach: Nanomicelle-Loaded In Situ Gels

While nanomicelles and in situ gels are powerful platforms individually, their true potential is unlocked when they are combined. This synergistic approach creates a multi-stage delivery system that simultaneously addresses the two most significant barriers to topical ocular drug delivery: rapid precorneal clearance and poor transcorneal permeation. This section explores the rationale, formulation, and mechanism of this innovative combination.

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

4.1. Rationale for Combination: A "Two-Stage" Delivery Strategy

The combination of nanomicelles within an in situ gelling system creates a sophisticated, two-stage delivery cascade:

- **Stage 1: The Macro-Reservoir.** Upon instillation, the low-viscosity polymer solution containing the nanomicelles instantly forms a gel on the ocular surface. This gel acts as a stationary "macro-reservoir" or depot. Its primary function is to adhere to the precorneal area, resisting tear washout and dramatically prolonging the residence time of the entire formulation [46].
- **Stage 2: The Nano-Shuttle.** From this gel depot, the drug-loaded nanomicelles are released in a sustained and controlled manner. These nanomicelles then function as "nano-shuttles." Their small size and optimized surface chemistry enable them to diffuse through the gel matrix, navigate the tear film's mucus layer, and effectively transport their poorly soluble drug cargo across the corneal and/or conjunctival barriers into the intraocular tissues [47].

This dual strategy is inherently synergistic. The in situ gel solves the problem of retention, ensuring a sustained supply of the drug carrier. The nanomicelles solve the problems of drug solubility and membrane permeation. Neither platform alone can effectively address all these challenges simultaneously. A simple nanomicelle solution would be cleared from the eye too quickly, while an in situ gel carrying a free, poorly soluble drug would suffer from inefficient release and low permeation. The combination leverages the strengths of both technologies to create a far more effective delivery system.

4.2. Formulation, Development, and Characterization

The development of a nanomicelle-loaded in situ gel is typically a two-step process that requires careful optimization to ensure the stability and performance of the final product.

Preparation Method

1. Preparation of Drug-Loaded Nanomicelles: The first step involves creating the nanomicellar dispersion. A common technique is the thin-film hydration method. The drug and the amphiphilic polymer/surfactant are dissolved in an organic solvent, which is then evaporated under vacuum to form a thin film. This film is subsequently hydrated with an aqueous buffer and sonicated, causing the amphiphiles to self-assemble into drug-loaded nanomicelles [32, 48].

2. Incorporation into the In Situ Gel Base: The pre-formed nanomicellar dispersion is then gently mixed into the solution of the stimuli-responsive polymer (e.g., Poloxamer 407, Gellan Gum) under conditions that maintain its liquid state (e.g., low temperature for thermo-responsive gels) [46]. The final formulation is a low-viscosity liquid containing a homogenous dispersion of the nanocarriers.

Critical Quality Attributes (CQAs)

For both academic research and industrial development, a series of critical quality attributes must be rigorously evaluated to ensure the safety, stability, and efficacy of the formulation [49]:

Nanomicelle Properties:

- **Particle Size and Polydispersity Index (PDI):** Measured by Dynamic Light Scattering (DLS). A small size (<100 nm) and low PDI (<0.3) are desirable for efficient permeation and formulation uniformity.
- **Zeta Potential:** Indicates the surface charge of the micelles, which influences their stability (preventing aggregation) and interaction with negatively charged ocular surfaces.
- **Entrapment Efficiency (EE%) and Drug Loading (DL%):** Quantifies the percentage of the initial drug that is successfully encapsulated within the micelles. High EE% is crucial for an efficient delivery system.

In Situ Gel Properties:

- **Clarity and Appearance:** The formulation must be clear both before and after gelation to avoid blurred vision.
- **pH and Osmolality:** Must be within the physiologically tolerated range (pH 6.5-7.6, Osmolality ~300 mOsm/kg) to prevent ocular irritation.
- **Rheological Properties:** Viscosity measurements are critical to confirm the sol-to-gel transition. The formulation should have low viscosity in the sol state for easy instillation and high viscosity in the gel state for prolonged retention.
- **Gelling Temperature/Time:** For thermo-responsive systems, the gelation temperature should be between room temperature and eye temperature. For ion/pH-activated systems, gelation should be rapid upon contact with simulated tear fluid.

Combined System Performance:

- **In Vitro Drug Release:** Using a dialysis bag method, the release profile is studied over time to confirm sustained release from the combined system compared to the nanomicelle solution alone.
- **Mucoadhesive Strength:** Measures the force required to detach the gel from a mucosal surface (e.g., porcine cornea), quantifying its retention capability.

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

- **Ex Vivo Permeation:** Using freshly excised animal corneas (e.g., goat, rabbit) mounted in a Franz diffusion cell, this study quantifies the amount of drug that permeates the tissue over time, providing a direct measure of the formulation's ability to enhance penetration.

4.3. Mechanism of Action in Uveitis Therapy

The complete journey of a drug molecule from the bottle to its site of action in the inflamed eye via this advanced system can be visualized as a multi-step process, elegantly illustrated in Figure 3.



Figure 3. A detailed schematic illustrating the synergistic mechanism of a nanomicelle-loaded in situ gel. (1) Instillation of the low-viscosity liquid formulation. (2) Rapid sol-to-gel transition triggered by ocular physiology (temperature, pH, ions), forming a mucoadhesive depot. (3) Sustained release of drug-loaded nanomicelles from the gel matrix. (4) Nanomicelles penetrate the corneal/conjunctival barriers. (5) The drug is released from the nanomicelles at the target site (e.g., iris-ciliary body) to exert its anti-inflammatory effect.

This integrated system effectively creates a non-invasive, topical drug depot that provides both sustained delivery and enhanced penetration, a combination that is unattainable with conventional eye drops. By maintaining a steady, therapeutic concentration of an anti-inflammatory agent at the site of inflammation for an extended period, it has the potential to control uveitis more effectively, with a lower dosing frequency and a superior safety profile.

5. Therapeutic Efficacy: Analysis of Preclinical and In Vivo Studies

The theoretical advantages of combining nanomicelles with in situ gels have been substantiated by a growing body of preclinical research. These studies, primarily using rabbit models of endotoxin-induced uveitis (EIU)—a standard model for acute anterior uveitis—have provided compelling evidence of the platform's superior therapeutic efficacy compared to conventional formulations. This section analyzes key findings for the delivery of both corticosteroids and immunosuppressants.

5.1. Delivery of Corticosteroids:

Corticosteroids are the first-line treatment for uveitis, but their poor water solubility presents a major formulation challenge. The nanomicelle-gel platform directly addresses this issue, leading to significant improvements in performance.

Dexamethasone & Prednisolone

Dexamethasone (DEX) is a potent corticosteroid widely used for ocular inflammation. However, its hydrophobicity limits its formulation as a clear solution. Studies by Chowdhury et al. pioneered the development of a 0.1% DEX-loaded nanomicellar system incorporated into an ion-sensitive in situ gel [50, 51]. Their work, along with similar research on prednisolone by Kaushal et al. [52], demonstrated several key advantages:

- **Enhanced Formulation:** They successfully formulated a clear aqueous solution of a hydrophobic steroid, a significant improvement over milky suspensions that cause blurred vision and dose non-uniformity.
- **Sustained Release:** In vitro release studies consistently showed a biphasic release pattern: an initial burst followed by a sustained release over 24 to 48 hours. This contrasts sharply with the rapid, almost complete release from a simple drug solution within a few hours [50, 52].
- **Superior Permeation:** Ex vivo permeation studies using porcine or goat corneas revealed a significant increase in drug transport. For instance, the nanomicelle-gel system often showed a 2- to 3-fold increase in the amount of drug permeated compared to a conventional suspension, attributed to the combined effect of prolonged contact time from the gel and the permeation-enhancing properties of the nanomicelles [51].
- **Improved In Vivo Efficacy:** In EIU rabbit models, the therapeutic effect was markedly superior. Treatment with the nanomicelle-gel formulation led to a more rapid and profound reduction in clinical signs of inflammation, such as anterior chamber cell count, flare (protein leakage), and iris vasodilation, compared to commercial DEX suspensions. Crucially, this enhanced efficacy was achieved with a reduced dosing frequency (e.g., twice daily vs. four times daily), highlighting the platform's potential to improve patient compliance [53].

Difluprednate

Difluprednate is a more potent corticosteroid marketed as a 0.05% emulsion (Durezol®). While effective, the emulsion formulation can cause ocular discomfort and requires dosing up to four

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

times a day for uveitis [54]. Recent research by Sathe et al. focused on developing a nanomicellar formulation of difluprednate (named Dicel) to overcome these limitations [32]. Their findings are highly relevant:

- **Formulation and Stability:** They created a stable nanomicellar formulation with a particle size of ~22 nm, which was biocompatible and stable upon dilution with simulated tear fluid.
- **Enhanced Permeation and Release:** The nanomicelles demonstrated a twofold enhancement in corneal permeation compared to the commercial emulsion and showed a sustained release profile for 48 hours.
- **Potent Anti-inflammatory Activity:** In an EIU model, the nanomicellar formulation showed improved anti-inflammatory activity when administered only once or twice a day, compared to the four-times-a-day regimen required for the commercial emulsion [32].

Although this study focused on nanomicelles alone, it logically follows that incorporating this highly effective nanomicellar system into an in situ gel would further amplify these benefits by adding the dimension of prolonged precorneal retention, potentially allowing for a true once-daily, non-invasive, potent corticosteroid therapy for anterior uveitis.

5.2. Delivery of Immunosuppressants

Developing topical formulations for steroid-sparing agents like cyclosporine is a major goal for managing chronic ocular inflammation and dry eye disease, which often coexists with uveitis.

Cyclosporine A (CyA)

Cyclosporine A is a highly hydrophobic and large molecule (1202.6 Da), making its topical delivery exceptionally difficult. Commercial formulations like Restasis® (0.05% emulsion) and Ikervis® (0.1% emulsion) have low bioavailability. The approval of Cequa® (0.09% nanomicellar solution) marked a significant step forward, validating the clinical utility of nanomicelles for CyA delivery [55].

Building on this, the work by Terreni et al. represents a key advancement by combining CyA nanomicelles with an ion-sensitive in situ gel [46].

Their comprehensive study highlighted:

- **Superior Formulation:** They developed a clear, stable nanomicellar formulation using VitE-TPGS and Kolliphor® RH-40 that could solubilize 0.144% w/w of CyA, a higher concentration than existing commercial products.
- **Optimized Gelling System:** This nanomicellar dispersion was successfully incorporated into a gellan gum-based in situ gel that was clear, easy to instill, and demonstrated appropriate rheological properties and gelling capacity in the presence of simulated tear fluid.
- **Enhanced Pharmacokinetics:** A pivotal in vivo study in rabbits demonstrated that the combined nanomicelle-gel system significantly prolonged the residence time of CyA in the precorneal area compared to the commercial Ikervis® emulsion. This prolonged contact is a direct prerequisite for improved therapeutic effect.
- **Safety and Efficacy Profile:** The formulation was shown to be non-cytotoxic and, importantly, prevented transcorneal permeation of CyA, localizing its effect to the ocular surface and anterior segment, which is desirable for treating conditions like dry eye and anterior uveitis while minimizing deeper penetration [46].

Voclosporin & Other Calcineurin Inhibitors

Voclosporin, a novel and more potent calcineurin inhibitor, was developed for non-infectious uveitis in the LUMINATE trial program [56]. Nanomicellar formulations of voclosporin have been shown to achieve therapeutic concentrations in the retina and choroid after topical application in rabbits, demonstrating the power of nanomicelles to deliver drugs to the posterior segment [57, 58]. While these studies did not use an in situ gel, they establish the principle that a topical nanomicellar drop can reach the back of the eye. Combining such a potent posterior-penetrating nanomicelle with an in situ gel could create a groundbreaking, non-invasive, steroid-sparing therapy for intermediate and posterior uveitis, representing a holy grail in ocular drug delivery.

Drug(s)	Formulation Type	Key Findings	References
Dexamethasone, Prednisolone	Nanomicelle-loaded ion-sensitive in situ gel	Successfully created clear aqueous formulations of hydrophobic steroids. Showed sustained release over 24-48 hours and 2- to 3-fold increased corneal permeation. Achieved superior in vivo efficacy in EIU models with reduced dosing frequency.	Chowdhury et al. [50, 51], Kaushal et al. [52]
Difluprednate	Nanomicellar solution (Dicel)	Developed a stable, clear nanomicellar formulation (~22 nm). Demonstrated a 2-fold enhancement in corneal permeation and 48-hour sustained release compared to the	Sathe et al. [32]

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

		commercial emulsion. Showed improved anti-inflammatory activity with once/twice daily dosing vs. four times daily for the commercial product.	
Cyclosporine A (CyA)	Nanomicelle-loaded ion-sensitive in situ gel	Solubilized a higher concentration of CyA (0.144%) than commercial products. The combined system significantly prolonged precorneal residence time in rabbits compared to Ikervis® emulsion. Localized drug effect to the anterior segment.	Terreni et al. [46]
Voclosporin	Nanomicellar solution	Topical application achieved therapeutic drug concentrations in the posterior segment (retina and choroid) in rabbit models, demonstrating the potential for non-invasive treatment of posterior uveitis.	Velagaleti et al. [57], Gokulgandhi et al. [58]



Figure 4. Representative data compiled from literature showing the comparative advantages of the combined system. (A) In vitro drug release profile demonstrating sustained release from the Nanomicelle-Gel system compared to faster release from nanomicelles alone and burst release from a solution. (B) In vivo efficacy in an EIU model, showing a more significant and sustained reduction in ocular inflammation score with the Nanomicelle-Gel formulation compared to a conventional eye drop and placebo.

6. Challenges, Scalability, and Future Directions:

Despite the compelling preclinical evidence and strong scientific rationale, the path from a promising laboratory concept to a clinically approved and commercially viable product is fraught with challenges. The successful translation of nanomicelle-loaded in situ gels requires overcoming technical, manufacturing, and regulatory hurdles.

6.1. Current Hurdles and Limitations

Technical and Formulation Challenges

- **Formulation Complexity and Stability:** This is a dual system, and ensuring the long-term physical stability of the nanomicelles within the polymer matrix is non-trivial. Interactions between the surfactants/polymers of the micelles and the gelling polymer could lead to micelle aggregation, drug leakage, or altered gelation properties over time [59].
- **Viscosity and Patient Comfort:** While high viscosity is desired for retention, excessive viscosity can cause blurred vision and patient discomfort. The formulation must strike a delicate balance: the gel must be strong enough to resist washout but should exhibit shear-thinning properties, meaning its viscosity decreases during a blink to improve comfort and spreadability [41].
- **Drug Loading and Efficiency:** While nanomicelles significantly improve the solubility of hydrophobic drugs, achieving very high drug loading can sometimes be challenging and may compromise the stability of the micellar structure [28].

Manufacturing and Scalability

This is perhaps the most significant barrier from a pharmaceutical industry perspective. Transitioning the multi-step laboratory preparation process to a sterile, reproducible, and cost-effective large-scale Good Manufacturing Practice (GMP) operation is a major undertaking [60]. Key challenges include:

- **Sterilization:** Ophthalmic products must be sterile. Terminal sterilization by autoclaving can degrade both the drug and the polymers. Aseptic manufacturing is an alternative but is more complex and expensive [61].
- **Quality Control:** Ensuring batch-to-batch consistency for a complex system with multiple critical quality attributes (particle size, drug content, viscosity, gelling temperature) requires sophisticated analytical techniques and robust process controls [60].

Biocompatibility and Long-Term Safety

While many of the polymers and surfactants used are FDA-approved for ocular use, the long-term effects of chronic exposure to the high concentrations of these excipients required for micelle and gel formation are not fully known [62]. The delicate ocular surface, including the corneal epithelium and goblet cells, could be adversely affected over time. Comprehensive, long-term toxicology studies are essential to ensure the safety of this platform for chronic use in uveitis patients.

6.2. Regulatory and Clinical Translation Perspective:

Navigating the regulatory pathway for a combination product like this presents unique challenges. The formulation would likely be

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

reviewed as a drug-device combination, where the in situ gelling system is considered a delivery device component. While precedents exist for the approval of both nanomicellar solutions (e.g., Cequa®) and in situ gels (e.g., Timoptic-XE®), the combination of the two adds a layer of complexity to the regulatory submission [45, 55]. Regulators will require extensive data not only on the safety and efficacy of the final product but also on the interaction between its components and the robustness of the manufacturing process.

The successful clinical translation hinges on demonstrating a clear and significant clinical benefit—in terms of either superior efficacy or an improved safety/tolerability profile—over existing approved therapies in well-designed, randomized controlled trials.

6.3. Future Outlook and Innovations

The future of this platform is bright, with several exciting avenues for innovation that could further enhance its therapeutic potential:

- **Advanced "Smart" Materials:** The next generation of in situ gels could utilize "smart" polymers that respond not just to general physiological cues but to specific biomarkers of inflammation. For example, gels that degrade or release their drug payload in response to elevated levels of matrix metalloproteinases (MMPs) or specific pH changes present only in inflamed tissue would offer another layer of targeted delivery [63, 64].
- **Targeting Posterior Uveitis:** The ultimate goal remains the development of a topical drop that can reliably treat posterior segment diseases. By optimizing nanomicelle chemistry (e.g., using specific ligands or cell-penetrating peptides on the surface), it may be possible to enhance transport across the sclera and RPE to deliver therapeutic concentrations of drugs to the retina and choroid, potentially revolutionizing the treatment of posterior uveitis [58, 65].
- **Combination Therapy:** The platform is ideally suited for combination therapy. A single formulation could be co-loaded with two different drugs, such as a fast-acting corticosteroid for acute inflammation control and a slower-acting immunosuppressant for long-term maintenance. This could provide a multi-pronged attack on the inflammatory cascade from a single, convenient eye drop [66].
- **Gene Therapy and Biologics:** Looking further ahead, these systems could be adapted to deliver more complex therapeutics like siRNA to silence inflammatory genes or even fragments of biologic drugs, opening up entirely new, non-invasive treatment modalities [67, 68].

Ultimately, the progression of this technology will depend on robust clinical evidence. The field is in critical need of well-designed, randomized controlled trials in human patients to validate the promising preclinical findings. Such trials will be essential to establish a definitive clinical benefit and pave the way for regulatory approval, bringing this innovative therapy to the patients who need it most [69, 70].

7. CONCLUSION

Uveitis remains a formidable clinical challenge, where the efficacy of potent anti-inflammatory drugs is consistently undermined by the eye's natural defenses. The current treatment paradigm forces a difficult compromise between efficacy and safety, often relying on invasive procedures or systemic therapies with significant side-effect profiles. The synergistic combination of drug-loaded nanomicelles and stimuli-responsive in situ gels represents a highly promising, next-generation platform poised to disrupt this paradigm.

This comprehensive review has synthesized the evidence demonstrating how this dual-action system elegantly addresses the core challenges of topical ocular delivery. By encapsulating hydrophobic drugs, nanomicelles overcome solubility and permeation barriers, acting as efficient nano-shuttles to transport therapeutics into the eye. Simultaneously, the in situ gel acts as a mucoadhesive macro-reservoir, prolonging precorneal residence time and providing sustained, controlled release of these nanocarriers. Preclinical studies have consistently validated this approach, showing enhanced bioavailability, superior anti-inflammatory efficacy, and the potential for a significantly reduced dosing frequency compared to conventional formulations.

While significant hurdles in manufacturing, long-term safety validation, and regulatory navigation remain, the scientific foundation is strong. The potential to offer patients a non-invasive, effective, and convenient once- or twice-daily topical treatment for a condition that often requires frequent injections or toxic systemic drugs is a powerful motivator for continued research and development. As materials science and nanotechnology continue to advance, nanomicelle-loaded in situ gels hold the potential to shift the standard of care, improving not only clinical outcomes but also the quality of life for countless individuals affected by ocular inflammation.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

uveitis: the impact of research on clinical practice. Br J Ophthalmol. 2011;95(12):1632-1638.
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491-500.
3. Sivaraman A, Goldstein DA. Uveitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540993/.
4. Vadlapudi AD, Mitra AK. Nanomicelles: an emerging platform for drug delivery to the eye. Ther Deliv. 2014;5(5):485-487.
5. Yang P, Yang Z, Zhou H, et al. Gene therapy: New and future treatments for uveitis. Ocul Immunol Inflamm. 2024;32(1):1-11.
6. Mattapallil MJ, Caspi RR. Uveitis: Molecular Pathogenesis and Emerging Therapies. Front Immunol. 2021;12:692663.
7. Taylor SR, Habot-Wilner Z, Lightman S. The diagnosis and management of uveitic macular oedema. Ophthalmol Ther. 2012;1(1):3.
8. Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121(12):2387-2392.
9. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516.
10. Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious uveitis. Eye (Lond). 2012;26(1):17-28.
11. Sheppard JD, Toyos R, Kempen JH, et al. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci. 2014;55(5):2993-3002.
12. Goldstein DA, Godfrey DG, Hall A, et al. Dexamethasone drug-eluting implant for noninfectious intermediate, posterior, or panuveitis: a randomized, sham-controlled, multicenter trial. Arch Ophthalmol. 2008;126(11):1497-1505.
13. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932-943.
14. Kempen JH, Altaweel MM, Holbrook JT, et al. The Multicenter Uveitis Steroid Treatment (MUST) trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149(4):550-561.e10.
15. Oray M, Abu Samra K, Ebrahimiadib N, et al. Long-term side effects of corticosteroids. Expert Opin Drug Saf. 2016;15(4):457-465.
16. Galor A, Jabs DA. A review of steroid-sparing agents in the treatment of noninfectious uveitis. Ocul Immunol Inflamm. 2007;15(5):339-349.
17. Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863-1870.
18. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine for chronic, noninfectious uveitis. Am J Ophthalmol. 1991;112(2):138-146.
19. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious intermediate, posterior, or panuveitis controlled by systemic corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183-1192.
20. Suarez-Almazor ME, Belseck E, Shea B, et al. Adalimumab for treating uveitis. Cochrane Database Syst Rev. 2010;(3):CD007962.
21. Khadam S, Boddu SHS, Al-Janabi A, et al. Breaking Barriers in Ocular Drug Delivery for Uveitis. Eur J Pharm Sci. 2025;185:106421.
22. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-360.
23. Mishra GP, Tamboli V. Ocular drug delivery systems: a review. J Drug Deliv Ther. 2011;1(2):47-56.
24. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131-1135.
25. Cunha-Vaz J, Bernardes R, Lobo C. Blood-retinal barrier. Eur J Ophthalmol. 2011;21 Suppl 6:S3-S9.
26. Achouri D, Alhanout K, Rouzes C, et al. Recent advances in ocular drug delivery. Drug Dev Ind Pharm. 2013;39(11):1599-1617.
27. Patel A, Cholkar K, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47-64.
28. Gaucher G, Dufresne MH, Sant VP, et al. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109(1-3):169-188.
29. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21(2):107-116.
30. Vaishya RD, Gokulgandhi M, Patel S, et al. Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis. AAPS PharmSciTech. 2014;15(5):1143-1154.
31. Souto EB, Dias-Ferreira J, López-Machado A. Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics. 2019;11(9):460.
32. Sathe R, Nawale L, Shinde G, et al. A Nanomicelles Platform Delivery System for Water-Insoluble Corticosteroid to Treat Anterior Uveitis. AAPS PharmSciTech. 2025;26(1):103.
33. Cholkar K, Patel SP, Vadlapudi AD, Mitra AK. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. J Ocul Pharmacol Ther. 2014;30(2-3):160-173.
34. Gokulgandhi M, Vadlapudi A, Mitra AK. The role of P-glycoprotein (ABCB1) in the disposition of substrate drugs in the eye. Int J Pharm. 2012;434(1-2):398-409.
35. Torchilin VP. Structure and design of polymeric micelles. J Control Release. 2001;73(2-3):137-172.
36. Cai R, Zhang L, Chi H. Recent development of polymer nanomicelles in the treatment of eye diseases. Front Bioeng Biotechnol. 2023;11:1246974.
37. Shiraishi K, Kawano K, Minamitake Y, et al. Self-assembled latanoprost loaded soluplus nanomicelles as an effective topical ocular delivery system. Sci Rep. 2024;14(1):78244.
38. Patel S, Garapati C, Chowdhury P, et al. Development and Evaluation of Dexamethasone Nanomicelles with Improved Penetration for Posterior Uveitis. J Ocul Pharmacol Ther. 2015;31(4):215-224.
39. Lallemand F, Daull P, Benita S, et al. Successfully developing innovative ophthalmic formulations: a case study. J Drug Deliv. 2012;2012:604810.
40. Almeida H, Amaral MH, Lobão P, Lobo JM. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today. 2014;19(4):400-412.
41. Koffi A, Agnely F, Ponchel G. Temperature-responsive polymers for drug delivery: a review of mechanisms and applications. Expert Opin Drug Deliv. 2021;18(12):1769-1787.
42. Gupta H, Velpandian T, Jain S. Ion- and pH-activated in situ gel system for sustained ocular drug delivery. Drug Deliv. 2010;17(7):509-515.
43. Paulsson M, Håkansson A, Edsman K. Gellan gum as an in situ gelling vehicle in ophthalmology: effect of formulation variables on gelling and release properties. J Pharm Sci. 2001;90(10):1345-1353.
44. Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release. 2000;69(3):379-388.
45. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-

Journal of Molecular Science
Volume 35 Issue 3, Year of Publication 2025, Page 762-774
DoI-10.004687/1000-9035.2025.103

forming ophthalmic drug delivery system from a mucoadhesive polymer (Regel). J Control Release. 1997;44(2-3):201-208.
46. Terreni E, Zucchetti E, Tampucci S, et al. Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A. Pharmaceutics. 2021;13(2):192.
47. Nirbhavane P, Sharma G, Sharma R, et al. Steroidal nanoformulations for the treatment of uveitis: potential, promises and future perspectives. Int Ophthalmol. 2024.
48. Alimardani V, Abolmaali SS, Yousefi G, et al. In-situ nanomicelle forming microneedles of poly NIPAAm-b-poly glutamic acid for trans-scleral delivery of dexamethasone. J Ind Eng Chem. 2023;117:345-356.
49. Wu KY, Tan K, Akbar D, et al. A New Era in Ocular Therapeutics: Advanced Drug Delivery Systems for Uveitis and Neuro-Ophthalmologic Conditions. Pharmaceutics. 2023;15(7):1952.
50. Chowdhury P. Development and Preliminary In vitro Evaluation of Nanomicelles Laden In situ Gel of Dexamethasone for Ophthalmic Delivery. University of Toledo Health Science Campus / OhioLINK; 2015.
51. Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. Nanomedicine (Lond). 2014;9(7):1109-1127.
52. Kaushal N, Kumar M, Tiwari A, et al. Polymeric Micelles Loaded In Situ Gel with Prednisolone Acetate for Ocular Inflammation: Development and Evaluation. Nanomedicine. 2023;18(25):1885-1901.
53. Alami-Milani M, Zakeri-Milani P, Valizadeh H, et al. Dexamethasone-loaded PCL-PEG-PCL micelles for treatment of anterior uveitis. J Drug Deliv Sci Technol. 2018;47:487-494.
54. Foster CS, Davanzo R, Flynn TE, et al. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26(5):475-483.
55. Tauber J, Schechter BA, Bacharach J, et al. A Phase III, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% for the Treatment of Dry Eye Disease. Ophthalmology. 2018;125(9):1357-1364.
56. Aris IM, Nussenblatt RB. Voclosporin: a novel calcineurin inhibitor for treatment of noninfectious uveitis. Expert Opin Investig Drugs. 2011;20(10):1423-1428.
57. Velagaleti P, Rapalli VK, Singhvi G. Voclosporin for Noninfectious Uveitis Involving the Posterior Segment. Invest Ophthalmol Vis Sci. 2016;57(12):5421.
58. Gokulgandhi M, Cholkar K, Mitra AK. A new agent for the treatment of noninfectious uveitis: voclosporin. Clin Ophthalmol. 2009;3:223-231.
59. Pandey M, Choudhury H, Abd Aziz A, et al. Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research. Polymers (Basel). 2021;13(8):1340.
60. Ghataliya V, Vadlapudi AD, Mitra AK. Ocular Drug Delivery: Present Innovations and Future Challenges. J Pharmacol Exp Ther. 2019;370(3):602-624.
61. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Sterilization of ocular preparations. Adv Drug Deliv Rev. 2004;56(3):325-338.
62. Liu LC, Chen YH, Lu DW. Overview of Recent Advances in Nano-Based Ocular Drug Delivery. Int J Mol Sci. 2023;24(20):15352.
63. Lyu C, Wang Y, Zhang H, et al. Intellective and stimuli-responsive drug delivery systems in eyes. Int J Pharm. 2021;607:121008.
64. Wu K, Truong D, Tran SD. Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications. Smart Molecules. 2024;2(1):e20230021.
65. Mehra N, Aqil M, Sultana Y. A grafted copolymer-based nanomicelles for topical ocular delivery of everolimus: Formulation, characterization, ex-vivo permeation, in-vitro ocular toxicity, and in-vivo anti-inflammatory activity. Eur J Pharm Sci. 2021;159:105713.
66. Wei J, Mu J, Tang Y, et al. Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy. J Nanobiotechnol. 2023;21(1):284.
67. Sarkar A, Dyawanapelly S. External stimuli-responsive drug delivery to the posterior segment of the eye. J Control Release. 2024;370:1-16.
68. Yang P, Zhou H, Chen Y, et al. Gene therapy for non-infectious uveitis: a review. Eye Vis (Lond). 2022;9(1):28.
69. Rathinam SR, Gonzales JA, Thundikandy R, et al. A systematic review of clinical trials in uveitis: lessons learned. Expert Rev Ophthalmol. 2022;17(5):345-357.
70. Dick AD, Tufail A, Tundia N, et al. Pharmacotherapy for non-infectious uveitis: spotlight on phase III clinical trials. Expert Opin Pharmacother. 2023;24(1):103-115.